LAVAL, Quebec–(BUSINESS WIRE)–Altasciences è lieta di annunciare che il recente lavoro di formulazione a sostegno di 4B Healthcare Inc. (“4B”) ha contribuito a portare la sua terapia liquida per irrigazione nasale RhineX nella fase di sperimentazione clinica. Dopo vari mesi di sviluppo della formulazione, produzione in ambito di ricerca e sviluppo, prove di stabilità e controlli di qualità presso l’impianto CDMO di Altasciences a Harleysville, PA, la società farmaceutica con sede nel Tennesse
Month: September 2026
LOS ANGELES–(BUSINESS WIRE)– #ElevatorIndustry–Total Access Elevator Continues to Grow with the Acquisition of American Elevator Inc.
LAVAL, Quebec–(BUSINESS WIRE)–Altasciences tiene el orgullo de anunciar que el reciente trabajo de formulación junto con 4B Healthcare Inc. (“4B”) ayudó a que el enjuague nasal con esteroides llegue a la fase de investigación clínica. Tras varios meses de desarrollo de la formulación, fabricación en I+D, pruebas de estabilidad y control de calidad en el centro de la organización de desarrollo y fabricación por contrato (CDMO) de Altasciences ubicado en Harleysville (Pensilvania), la empresa f
LAVAL, Québec–(BUSINESS WIRE)–Altasciences ist stolz darauf, bekannt geben zu können, dass die jüngsten Arbeiten zur Formulierung zugunsten von 4B Healthcare Inc. („4B“) dazu beigetragen haben, die nasale Spültherapie „RhineX“ in die klinische Erprobung zu bringen. Nach mehrmonatiger Arbeit an der Formulierung, der Forschung und Entwicklung, der Herstellung, den Stabilitätstests und der Qualitätssicherung in der CDMO-Anlage von Altasciences in Harleysville, Pennsylvania, hat das in Tennessee
LAVAL, Québec–(BUSINESS WIRE)–Altasciences est fière d’annoncer que ses récents travaux de formulation menés en soutien à 4B Healthcare Inc. (« 4B ») ont contribué à faire passer le traitement par rinçage nasal RhineX de 4B au stade de l’essai clinique. Après plusieurs mois consacrés au développement de la formulation, à la production en R&D, aux tests de stabilité et au contrôle qualité sur le site CDMO d’Altasciences à Harleysville, en Pennsylvanie, l’entreprise pharmaceutique basée dan
LAVAL, Québec–(BUSINESS WIRE)–Altasciences maakt trots bekend dat recent formulewerk ter ondersteuning van 4B Healthcare Inc. (“4B”) geholpen heeft om de RhineX neusspoeltherapie naar klinisch onderzoek te brengen. Na verschillende maanden ontwikkeling van de formule, R&D-productie, stabiliteitsproeven en kwaliteitsborgingsondersteuning bij de CDMO-faciliteit van Altasciences in Harleysville, PA, ontving het farmaceutische bedrijf gevestigd in Tennessee toestemming van de FDA om verder te
TOKYO–(BUSINESS WIRE)–NTT DOCOMO BUSINESS, Inc. (già NTT Communications Corporation) oggi ha annunciato il lancio di “Pro”, una nuova offerta all’interno della gamma docomo business SIGN®1, un servizio NaaS (network-as-a-service) focalizzato sull’IoT con funzionalità di sicurezza integrate. Progettato per supportare la diffusione globale e su larga scala di prodotti connessi, “Pro” aiuta i clienti a far funzionare e gestire decine di migliaia di connessioni IoT. Il servizio sarà disponibile a
NEW YORK–(BUSINESS WIRE)—- $HONA #ClassActionLawsuit–The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Honeywell Aerospace Inc. (“Honeywell Aerospace” or the “Company”) (NASDAQ: HONA) securities between June 29, 2026 and September 1, 2026, inclusive (“the Class Period”). If you suffered a loss on your Honeywell Aerospace investments, you have until November 23, 2026 to request lead plaintiff appointment.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]Inv
Company Announcement
COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company’s subsidiaries.
Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,268.
The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units.
The exercise price for each warrant is DKK 2,268. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 781.96.
The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow us on LinkedIn, X, Facebook and Instagram.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
Company Announcement no. 38
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
Attachment
紐約–(BUSINESS WIRE)–(美國商業資訊)– 數位資產基礎設施公司BitGo Holdings, Inc.（NYSE: BTGO，以下簡稱「BitGo」或「該公司」）今天宣布任命Greg Cipolaro為研究主任，同時成立「BitGo Research」。BitGo Research這組新團隊負責為客戶提供資料驅動分析，分析重點包括數位資產市場、市場結構以及整個產業的新興趨勢。 BitGo不久前收購了NYDIG的機構交易業務，Cipolaro先生當時擔任NYDIG的全球研究主任，決定在收購完成後加入BitGo。他在NYDIG建立並主導一組研究團隊，在比特幣及數位資產市場研究領域享有盛譽。該團隊定期發表市場評論與分析，深獲這個資產類別的機構投資者、資產配置方及企業信賴。 BitGo Research將憑藉BitGo在數位資產生態系統中的託管、交易、融資及結算業務核心地位，為該公司的機構客戶群持續提供市場評論、專題報告與受資料據驅動的分析。這組團隊將為那些希望深入了解市場結構、宏觀趨勢及數位資產格局的客戶提供可參考的資源。 「Greg在數位資產研究領域備受敬重，他的專業